| (a) Humans.
(1) Identification of notifiable conditions.
(A) A summary list of notifiable conditions and reporting
time frames is published on the Department of State Health Services
web site at http://www.dshs.state.tx.us/idcu/investigation/conditions/.
Copies are filed in the Emerging and Acute Infectious Disease Branch,
Department of State Health Services, 1100 West 49th Street, Austin,
Texas 78756.
(B) Repetitive test results from the same patient do
not need to be reported except those for mycobacterial infections.
(2) Notifiable conditions or isolates.
(A) Confirmed and suspected human cases of the following
diseases/infections are reportable: acquired immune deficiency syndrome
(AIDS); amebic meningitis and encephalitis; anaplasmosis; ancylostomiasis;
anthrax; arboviral infections including, but not limited to, those
caused by California serogroup virus, chikungunya virus, dengue virus,
Eastern equine encephalitis (EEE) virus, St. Louis encephalitis (SLE)
virus, Western equine encephalitis (WEE) virus, yellow fever virus,
West Nile (WN) virus, and Zika virus; ascariasis; babesiosis; botulism,
adult and infant; brucellosis; campylobacteriosis; Candida auris; carbapenem resistant Enterobacteriaceae (CRE); Chagas disease;
chancroid; chickenpox (varicella); Chlamydia
trachomatis infection; cryptosporidiosis; cyclosporiasis; diphtheria;
echinococcosis; ehrlichiosis; fascioliasis; gonorrhea; Haemophilus influenzae, invasive; Hansen's
disease (leprosy); hantavirus infection; hemolytic uremic syndrome
(HUS); hepatitis A, acute hepatitis B infection, hepatitis B acquired
perinatally (child), any hepatitis B infection identified prenatally
or at delivery (mother), acute hepatitis C infection, and acute hepatitis
E infection; human immunodeficiency virus (HIV) infection; influenza-associated
pediatric mortality; legionellosis; leishmaniasis; listeriosis; Lyme
disease; malaria; measles (rubeola); meningococcal infection, invasive;
mumps; novel coronavirus; novel influenza; paragonimiasis; pertussis;
plague; poliomyelitis, acute paralytic; poliovirus infection, non-paralytic;
prion diseases, such as Creutzfeldt-Jakob disease (CJD); Q fever;
rabies; rubella (including congenital); salmonellosis, including typhoid
fever; Shiga toxin-producing Escherichia
coli infection; shigellosis; smallpox; spotted fever group
rickettsioses (such as Rocky Mountain spotted fever); streptococcal
disease: Streptococcus pneumoniae, invasive;
syphilis; Taenia solium and undifferentiated Taenia infections, including cysticercosis;
tetanus; tick-borne relapsing fever; trichinosis; trichuriasis; tuberculosis (Mycobacterium tuberculosis complex); tuberculosis
infection; tularemia; typhus; vancomycin-intermediate Staphylococcus aureus (VISA); vancomycin-resistant Staphylococcus aureus (VRSA); Vibrio infection, including cholera (specify
species); viral hemorrhagic fever; and yersiniosis.
(B) In addition to individual case reports, any outbreak,
exotic disease, or unusual group expression of disease that may be
of public health concern should be reported by the most expeditious
means.
(3) Minimal reportable information requirements. The
minimal information that shall be reported for each disease is as
follows:
(A) AIDS, chancroid, Chlamydia
trachomatis infection, gonorrhea, HIV infection, and syphilis
shall be reported in accordance with Subchapter F of this chapter
(relating to Sexually Transmitted Diseases Including Acquired Immune
Deficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV));
(B) for tuberculosis disease - complete name, date
of birth, physical address and county of residence, country of origin,
information on which diagnosis was based or suspected. In addition,
if known, radiographic or diagnostic imaging results and date(s);
all information necessary to complete the most recent versions of
department reporting forms: Report of Case and Patient Services, Report
of Follow-up and Treatment for Contacts to TB Cases and Suspects;
and Report of Verified Case of Tuberculosis; laboratory results used
to guide prescribing, monitoring or modifying antibiotic treatment
regimens for tuberculosis to include, but not limited to, liver function
studies, renal function studies, and serum drug levels; pathology
reports related to diagnostic evaluations of tuberculosis; reports
of imaging or radiographic studies; records of hospital or outpatient
care to include, but not limited to, histories and physical examinations,
discharge summaries and progress notes; records of medication administration
to include, but not limited to, directly observed therapy (DOT) records,
and drug toxicity and monitoring records; a listing of other patient
medications to evaluate the potential for drug-drug interactions;
and copies of court documents related to court ordered management
of tuberculosis.
(C) for contacts to a known case of tuberculosis -
complete name; date of birth; physical address; county of residence;
evaluation and disposition; and all information necessary to complete
the most recent versions of department reporting forms: Report of
Follow-up and Treatment for Contacts to TB Cases and Suspects; and
Report of Case and Patient Services;
(D) for other persons identified with tuberculosis
infection - complete name; date of birth; physical address and county
of residence; country of origin; diagnostic information; treatment
information; medical and population risks; and all information necessary
to complete the most recent versions of department reporting form:
Report of Case and Patient Services.
(E) for hepatitis B (chronic and acute) identified
prenatally or at delivery - mother's name, address, telephone number,
age, date of birth, sex, race and ethnicity, preferred language, hepatitis
B laboratory test results; estimated delivery date or date and time
of birth; name and phone number of delivery hospital or planned delivery
hospital; name of infant; name, phone number, and address of medical
provider for infant; date, time, formulation, dose, manufacturer,
and lot number of hepatitis B vaccine and hepatitis B immune globulin
administered to infant;
(F) for hepatitis A, B, C, and E - name, address, telephone
number, age, date of birth, sex, race and ethnicity, disease, diagnostic
indicators (diagnostic lab results, including all positive and negative
hepatitis panel results, liver function tests, and symptoms), date
of onset, pregnancy status, and physician or practitioner name, address,
and telephone number;
(G) for hepatitis B, perinatal infection - name of
infant; date of birth; sex; race; ethnicity; name, phone number and
address of medical provider for infant; date, time, formulation, dose,
manufacturer, and lot number of hepatitis B vaccine and hepatitis
B immune globulin administered to infant, hepatitis B laboratory test
results;
(H) for chickenpox - name, date of birth, sex, race
and ethnicity, address, date of onset, and varicella vaccination history;
(I) for Hansen's disease - name; date of birth; sex;
race and ethnicity; disease type; place of birth; address; telephone
number; date entered Texas; date entered U.S.; education/employment;
insurance status; location and inclusive dates of residence outside
U.S.; date of onset and history prior to diagnosis; date of initial
biopsy and result; disease type i.e., tuberculoid, borderline and
lepromatous; date initial drugs prescribed and name of drugs; name,
date of birth and relationship of household contacts; and name, address,
and telephone number of physician or practitioner;
(J) for novel influenza investigations occurring during
an influenza pandemic--minimal reportable information on individual
cases, a subset of cases or aggregate data will be specified by the
department;
(K) for all other notifiable conditions listed in paragraph
(2)(A) of this subsection - name, address, telephone number, age,
date of birth, sex, race and ethnicity, disease, diagnostic indicators
(diagnostic lab results, specimen source, test type, and clinical
indicators), date of onset, and physician or practitioner name, address,
and telephone number; and
(L) other information may be required as part of an
investigation in accordance with Texas Health and Safety Code, §81.061.
(4) Diseases requiring submission of cultures. For
all anthrax (Bacillus anthracis); botulism,
adult and infant (Clostridium botulinum); brucellosis (Brucella species); Candida
auris; diphtheria (Corynebacteria
diphtheria from any site); all Haemophilus
influenzae, invasive, in children under five years old (Haemophilus influenzae from normally sterile
sites); listeriosis (Listeria monocytogenes); meningococcal
infection, invasive (Neisseria meningitidis from
normally sterile sites or purpuric lesions); plague (Yersinia pestis); salmonellosis, including
typhoid fever (Salmonella species);
Shiga toxin-producing Escherichia coli infection
(E.coli O157:H7, isolates or specimens
from cases where Shiga toxin activity is demonstrated); Staphylococcus aureus with a vancomycin
MIC greater than 2 µg/mL; all Streptococcus
pneumoniae, Cont'd... |
